Eli Lilly: Kisunla (donanemab) approved in the UK
(CercleFinance.com) - Eli Lilly announced today that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for donanemab, an injection for intravenous infusion every four weeks to treat mild cognitive impairment and mild dementia due to Alzheimer's disease in eligible adults in the UK.
Donanemab is the only treatment targeting amyloid plaques for which there is evidence to justify discontinuing treatment once the amyloid plaques have been eliminated. The UK is the third major market to approve donanemab, marketed under the brand name Kisunla.
This approval in the UK is an important step in ensuring that Alzheimer's patients can receive treatment with this new class of amyloid-targeting therapies, Lilly International said.
Currently, an estimated 982,000 people suffer from dementia in the UK, of which 50%-75% is attributable to Alzheimer's disease.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Donanemab is the only treatment targeting amyloid plaques for which there is evidence to justify discontinuing treatment once the amyloid plaques have been eliminated. The UK is the third major market to approve donanemab, marketed under the brand name Kisunla.
This approval in the UK is an important step in ensuring that Alzheimer's patients can receive treatment with this new class of amyloid-targeting therapies, Lilly International said.
Currently, an estimated 982,000 people suffer from dementia in the UK, of which 50%-75% is attributable to Alzheimer's disease.
Copyright (c) 2024 CercleFinance.com. All rights reserved.